Shaping the Future of Cancer
Transforming Cancer Treatment with Novel Targets
Taking Cancer Therapy to the Next Level
Sathgen Therapeutics is a clinical-stage biotech company working on bringing the first-in-class and best-in-class drugs ensuring novel treatments for difficult-to-treat cancers and potentially viral infections.
Our Trajectory
Our lead drug candidate is in phase I clinical trials in patients with advanced solid tumors, as well as in healthy individuals – to evaluate safety, tolerability and pharmacokinetics of the drug.
February 2023
Initiation of phase I trials of MSP008-22 in patients with advanced solid tumors.
April 2023
Initiation of phase I trials of MSP008-22 in healthy individuals.
June 2023
Completion of the dosing of the first cohort of patients in the phase I clinical trial of MSP008-22.
May 2025
Ongoing safety and efficacy studies.
Xenograft studies with triple negative breast cancer cells show tumor growth inhibition upon single arm MSP008-22 or in combination with standard-of-care chemotherapy, Carboplatin.
MSP008-22 improves the efficacy and lowers toxicity of another standard-of-care chemotherapy, Cisplatin, as shown by decreased IC50.
MSP008-22 shows excellent safety profile in pre-clinical models including induced human blood lymphocytes.
MSP008-22 also shows anti-stem cell and anti-metastatic efficacy in breast and prostate cancer models, in vitro.
Treatment with MSP008-22, both post-infection or prophylactic, reduces the SARS-CoV-2 viral load, and COVID-19-asscoiated Pneumonitis, alveolar injury, and inflammation score.
MSP008-22 inhibits viral replication to the same extent as the anti-viral, Remdesivir.
MSP008-22 shows anti-SARS-CoV-2 potential as observed in cytopathic assays, comparable to Remdesivir.
Financial and Technical Support
Sathgen Therapeutics has strong financial and technical support to help achieve its goals. We are backed by Godavari Biorefineries Limited (GBL), and linked to the Somaiya Group, which is actively involved in healthcare and education. Our CRO partner, Clinexel, provides expertise in early-stage clinical development and capabilities for global clinical development. With the support of our partners, we are confident that we can bring new and innovative therapies to patients in need.
Lets talk
For Investors
We are actively advancing MSP008-22 toward clinical development and welcome strategic partnerships to accelerate its path to market.
Robust Pipeline
Impactful Investment
Drug Class and Indications
Global Patents
Drug Development & Commercialization
Patent for MSP008-22 anti-cancer compound granted in USA and Japan.
Patent for Synthesis of Cleistanthin A and its derivatives thereof granted in India, USA, Germany, Netherlands, France, UK, Mexico, South Africa, Australia, New Zealand, Israel, Japan, and Canada.
Patent for Process for Synthesis of Cleistanthin granted in India, Australia, New Zealand, Mexico, Canada, UK, France, Netherlands, Germany, and South Africa
